The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Spatial transcriptomics analysis to predict response to immune checkpoint blockade (ICB) in recurrent or metastatic head and neck squamous cell cancer (RM-HNSCC).
 
Grégoire Marret
No Relationships to Disclose
 
Jinsu An
No Relationships to Disclose
 
Lucas Penny
No Relationships to Disclose
 
Ben Wang
No Relationships to Disclose
 
Azin Sayad
No Relationships to Disclose
 
Anna Spreafico
Consulting or Advisory Role - Alentis Therapeutics; Bristol-Myers Squibb; GlaxoSmithKline; Merck
Research Funding - Alentis Therapeutics (Inst); Alkermes (Inst); ALX Oncology (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Nubiyota (Inst); Pfizer (Inst); Replimune (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Symphogen (Inst); Teva (Inst); Treadwell Therapeutics (Inst)
 
Enrique Sanz Garcia
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline; GlaxoSmithKline; Novartis Canada Pharmaceuticals Inc; Rgenta (Inst); TEMPUS (Inst)
 
Aaron Hansen
Consulting or Advisory Role - Astellas Pharma; Bayer; Eisai; Janssen; Merck
Research Funding - Advancell (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Macrogenics (Inst); Merck (Inst); Roche/Genentech (Inst); Seagen (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Helen Chow
No Relationships to Disclose
 
Scott Bratman
No Relationships to Disclose
 
Pinaki Bose
No Relationships to Disclose
 
Lillian Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca; Daiichi Sankyo/UCB Japan; Gilead Sciences; GlaxoSmithKline; Incyte; LTZ Therapeutics; Marengo Therapeutics; Medicenna; Merck; Navire; Nerviano Medical Sciences; Pangea; Pangea; Relay Therapeutics; Roche; Seagen; Tubulis GmbH; Voronoi Health Analytics
Research Funding - 23andMe (Inst); Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); LegoChem Biosciences (Inst); Loxo/Lilly (Inst); Marengo Therapeutics (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Takara Bio (Inst)